Year: 2005
Type: article
Abstract: IN BRIEF Therapies based on the incretin hormone glucagon-like peptide 1 are novel treatment options for type 2 diabetes that act through a variety of complementary mechanisms. Exenatide, which will likely become the first application to reach the market, has shown promise in phase III trials in reducing hemoglobin A1c without causing significant hypoglycemia or weight gain.
Source: Clinical Diabetes
Authors: Kathleen Dungan, John B. Buse
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2150388129
